Who is sponsoring NCT04809740?

NCT04809740 is sponsored by University of Alabama at Birmingham.

Is NCT04809740 still recruiting?

NCT04809740 is currently completed. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT04809740

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Implementation and Impact of Navigator-delivered ePRO System

Completed NA Last updated 31 March 2026

What this trial tests

NA trial testing Evaluate implementation of navigator-delivered Home ePRO for all cancer patients in Cancer in 6,701 participants. Completed in 31 January 2026.

Timeline

4 May 2021

Primary endpoint
31 December 2025

31 January 2026

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	6,701
Start date	4 May 2021
Primary completion	31 December 2025
Estimated completion	31 January 2026
Sites	1 location across United States

Drugs / interventions tested

Evaluate implementation of navigator-delivered Home ePRO for all cancer patients

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

University of Alabama at Birmingham

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1\) Evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluating the implementation and impact of navigator-supported remote symptom monitoring and management: a protocol for a hybrid type 2 clinical trial.
Rocque GB, Dionne-Odom JN, Stover AM, Daniel CL, et al · · 2022 · cited 22× · PMID 35459238 · DOI 10.1186/s12913-022-07914-6
Engagement Among Diverse Patient Backgrounds in a Remote Symptom Monitoring Program.
Rocque GB, Caston NE, Hildreth K, Deng L, et al · · 2024 · cited 14× · PMID 38917385 · DOI 10.1200/op.24.00066
Evaluating Nurses' Time to Response by Severity and Cancer Stage in a Remote Symptom Monitoring Program for Patients With Breast Cancer.
Caston NE, Franks JA, Balas N, Eltoum N, et al · · 2023 · cited 10× · PMID 37279409 · DOI 10.1200/cci.23.00015
Remote Symptom Monitoring With Electronic Patient-Reported Outcomes in Clinical Cancer Populations.
Rocque GB, Franks JA, Deng L, Caston NE, et al · · 2025 · cited 9× · PMID 40358948 · DOI 10.1001/jamanetworkopen.2025.9852
Patient-Perceived Benefits and Limitations of Standard of Care Remote Symptom Monitoring During Cancer Treatment.
Smith CS, Henderson NL, Hendrix EK, Padalkar T, et al · · 2024 · cited 7× · PMID 39547695 · DOI 10.1177/10732748241297368

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04809740 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04809740.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing